Loading organizations...
§ Private Profile · Via Borgogna, 5, 20122 Milan, Italy
NanoPhoria is a technology company.
NanoPhoria develops inhalable cardiovascular treatments through its proprietary non-viral, nano-in-micro delivery platform for biologics. The company leverages an innovative approach utilizing inorganic calcium-phosphate nanoparticles as versatile carriers for therapeutic peptides and RNAs. Its lead product, NP-MP1, is an inhalable nano-in-micro formulation designed to deliver a specific calcium channel modulator peptide, aiming to address heart failure with reduced ejection fraction. This technology represents a novel method for tissue-directed therapeutic delivery.
The company was founded in 2022 by Claudio De Luca, who serves as CEO, and Daniele Catalucci, the Chief Scientific Officer. Their collaboration stemmed from a visionary peptide discovery, combining multidisciplinary expertise in molecular biology, nanotechnology, cardiology, and clinical development. This collective background provided the foundation for developing a targeted delivery system capable of reaching cardiac tissues efficiently via inhalation.
NanoPhoria primarily serves patients afflicted with heart failure with reduced ejection fraction, a chronic condition impacting millions globally. The company's overarching mission is to transform cardiology by developing powerful, inhaled therapeutics that offer meaningful treatment options. Its vision is centered on advancing these deep scientific innovations from preclinical stages through clinical trials, ultimately improving cardiovascular care for patients.
NanoPhoria has raised $118.4M across 2 funding rounds.
NanoPhoria has raised $118.4M in total across 2 funding rounds.
NanoPhoria has raised $118.4M across 2 funding rounds. Most recently, it raised $98.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $98M Series A | Soffinova Partners, CDP Venture Capital, Paolo Fundarò | Apollo Health Ventures, Broadview Ventures, Humboldt Fund, Panakes Partners | Announced |
| Feb 26, 2025 | $20.4M Grant | European Innovation Council | — | Announced |
NanoPhoria has raised $118.4M in total across 2 funding rounds.
NanoPhoria's investors include Soffinova Partners, CDP Venture Capital, Paolo Fundarò, Apollo Health Ventures, Broadview Ventures, Humboldt Fund, Panakes Partners, European Innovation Council.
NanoPhoria is a preclinical-stage biotech company developing inhalable cardiovascular treatments using a proprietary non-viral nano-delivery platform for biologics. Based in Milan, Italy, it focuses on tissue-directed delivery of therapeutic peptides and RNAs via inorganic calcium-phosphate nanoparticles, formulated for inhalation or other routes.[1][2][3] The lead product, NP-MP1, is an inhalable nano-in-micro formulation delivering a first-in-class peptide that modulates calcium channels to treat Heart Failure with reduced Ejection Fraction (HFrEF), a chronic condition affecting millions worldwide.[1][3] NanoPhoria serves patients with underserved cardiac conditions, solving the problem of targeted delivery to cardiomyocytes—previously inaccessible with existing treatments—through lung-to-heart technology that has shown promise in preclinical models.[1][3] The company has strong growth momentum, raising €83.5M ($98M) in an initial Series A closing led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, plus €17.5M from the European Innovation Council, funding IND-enabling trials, clinical development, manufacturing scale-up, and pipeline expansion.[2][3][5]
NanoPhoria was founded in 2022 as a spin-off from Italy's National Research Council (CNR), the country's largest public research institution. The four founders bring complementary backgrounds and remain actively involved, with the idea emerging from converging scientific expertise in nanotechnology and cardiovascular biology.[2][3][6] A pivotal moment came with early validation of their inorganic nanoparticle platform, leading to investments like Sofinnova Partners' backing via its Telethon strategy, which spotlights top Italian science.[2] Key milestones include publishing a groundbreaking study in a major cardiology journal, appointing Dr. Suman Shirodkar as chair and Prof. Michael Davidson as a non-executive board member, and securing major grants and funding to propel preclinical work toward clinical stages.[2]
NanoPhoria stands out in biotech through these key strengths:
NanoPhoria rides the wave of nanotechnology convergence with biologics delivery, particularly non-viral alternatives to gene therapies, amid rising demand for targeted cardiovascular treatments as heart disease remains a leading global killer.[1][3] Timing is ideal with Europe's biotech surge—fueled by EIC grants and VC focus on platform technologies—positioning Italy's research ecosystem (via CNR spin-offs) as a hub for innovation.[2][5][6] Market forces like aging populations, HFrEF's massive burden, and limitations of current oral/intravenous drugs favor inhalable solutions that bypass systemic issues for direct tissue action.[1][3] By advancing nano-in-micro tech, NanoPhoria influences the ecosystem, inspiring similar platforms and drawing capital to European cardio-biotech, potentially reshaping delivery for peptides/RNAs in chronic diseases.[2][3]
NanoPhoria's next milestones include IND submission, Phase 1 trials for NP-MP1, and pipeline expansion using its platform for additional indications. Trends like AI-optimized nanoparticles, combo therapies, and regulatory fast-tracks for heart failure will accelerate progress, with influence growing via board expertise and partnerships.[2][3] As it transitions from preclinical to clinic, expect broader adoption of its non-viral tech, transforming underserved cardiac care and solidifying its role as a Milanese biotech leader—pioneering inhalable hope for millions with HFrEF.[1][3]